Small molecule to potentially treat diabetes discovered in screening study
Posted: 22 June 2021 | Victoria Rees (Drug Target Review) | No comments yet
A small molecule found in a cell-based ultra-high-throughput screening campaign was shown to treat diabetes in cells and mice.


Scientists at the Scripps Research Institute, US, have identified a small molecule unfolded protein response (UPR) modulator, via a high-throughput screening study, that showed success at treating diabetes in cells and mice.
According to the researchers, there is evidence linking endoplasmic reticulum (ER) stress with impaired β-cell function in type 1 and 2 diabetes, as well as peripheral insulin resistance associated with type 2 diabetes. UPR is a stress response that is specific to the ER and is activated upon accumulation of unfolded (or misfolded) proteins in the ER’s lumen to restore protein folding capacity by increasing the synthesis of chaperones. In addition, UPR also enhances degradation of unfolded proteins and reduces protein synthesis to alleviate additional accumulation of unfolded proteins in the ER.
In their study, the team used a cell-based ultra-high-throughput screening (uHTS) campaign that revealed a small molecule that can modulate UPR and ER stress in cellular and in vivo disease models. Using asialoglycoprotein receptor 1 (ASGR) fused with Cypridina luciferase (CLuc) as a phenotypic reporter assay for folding capacity, the researchers screened a million small molecule library and identified APC655 as a potent activator of protein folding, which appears to act by promoting chaperone expression.
Automation now plays a central role in discovery. From self-driving laboratories to real-time bioprocessing
This report explores how data-driven systems improve reproducibility, speed decisions and make scale achievable across research and development.
Inside the report:
- Advance discovery through miniaturised, high-throughput and animal-free systems
- Integrate AI, robotics and analytics to speed decision-making
- Streamline cell therapy and bioprocess QC for scale and compliance
- And more!
This report unlocks perspectives that show how automation is changing the scale and quality of discovery. The result is faster insight, stronger data and better science – access your free copy today
Furthermore, the team found that APC655 improved pancreatic β-cell viability and insulin secretion under ER stress conditions induced by thapsigargin or cytokines. APC655 was also found to be effective at preserving β-cell function and decreasing lipid accumulation in the liver of the leptin-deficient mouse model.
The researchers say that these results demonstrate a successful uHTS campaign that identified a modulator of UPR, which could provide a novel candidate for potential therapeutic development to treat diabetes.
“The discovery of a small molecule that can improve the ER folding capacity by stimulating the chaperones expression and at the same time preserving cell viability, might be the key to preventing and/or curing many metabolic diseases,” the authors of the paper write.
The results from the study are published in Acta Pharmaceutica Sinica B.
Related topics
Drug Discovery, High-Throughput Screening (HTS), Metabolomics, Screening, Small Molecules
Related conditions
Diabetes, type 1 diabetes, Type-2 diabetes
Related organisations
The Scripps Research Institute







